Want to see RPRX full AI Analyst Report?
RPRX Stock Chart & Stats
$50.00
$0.10(0.38%)
At close: 4:00 PM EST
$50.00
$0.10(0.38%)
Day’s Range― - ―
52-Week Range$34.08 - $57.22
Previous CloseN/A
Volume726.99K
Average Volume (3M)4.24M
Market Cap
$32.29B
Enterprise Value$31.47B
Total Cash (Recent Filing)$608.29M
Total Debt (Recent Filing)$8.96B
Price to Earnings (P/E)22.9
Beta0.19
Next Earnings
Aug 12, 2026EPS Estimate
1.28Next Dividend Ex-DateN/A
Dividend Yield2.23%
Share Statistics
EPS (TTM)2.46
Shares Outstanding443,274,100
10 Day Avg. Volume3,841,502
30 Day Avg. Volume4,236,641
Financial Highlights & Ratios
PEG Ratio0.78
Price to Book (P/B)2.58
Price to Sales (P/S)7.02
P/FCF Ratio6.70
Enterprise Value/Market Cap0.97
Enterprise Value/Revenue12.89
Enterprise Value/Gross Profit12.90
Enterprise Value/Ebitda18.52
Forecast
1Y Price Target
$59.43Price Target Upside18.86% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)5.13
Revenue Forecast (FY)$3.45B
Bulls Say, Bears Say
Bulls Say
Cash GenerationVery strong and consistent cash generation provides durable capacity to fund acquisitions, support dividend increases and buybacks, and service interest. High FCF to net income and cash coverage (~4.9x) materially improve financial flexibility even if revenue timing fluctuates.
Recurring Royalty GrowthRecurring royalty receipts driven by multiple commercial products (e.g., Tremfya, Voranigo, Evrysdi) underpin predictable, long‑dated cash flows. That diversification across therapies and steady organic growth reduce reliance on single assets and support multi‑year revenue visibility.
Balance Sheet & LiquidityLong debt duration, an upgraded credit rating, and an undrawn revolver create durable access to capital for new royalty buys and co‑funding. The mix supports strategic dealmaking while covenant discipline and liquidity cushion reduce refinancing pressure over the medium term.
Bears Say
Elevated Interest ExpenseMaterial interest outlays are a persistent cash drag given sizeable debt stock. Semiannual timing swings can compress quarterly cash available for reinvestment or distributions, and higher-for-longer rates would structurally increase financing costs and reduce net cash returns.
Decline In Milestone ReceiptsMilestones are lumpy upside to returns; a sustained reduction cuts non‑recurring upside and makes growth more reliant on existing royalties and M&A. Lower milestone cadence reduces optional upside and complicates multi‑year cash‑flow modeling.
Execution And Optionality Risk In Co‑fundingDependence on partner choices for tranche draws creates uncertainty in deal realization and expected returns. Scaling co‑funding is operationally complex and optional tranches can leave projected royalty streams contingent, elevating execution risk to medium‑term growth plans.
Royalty Pharma News
RPRX FAQ
What was Royalty Pharma PLC’s price range in the past 12 months?
Royalty Pharma PLC lowest stock price was $34.08 and its highest was $57.22 in the past 12 months.
What is Royalty Pharma PLC’s market cap?
Royalty Pharma PLC’s market cap is $32.29B.
When is Royalty Pharma PLC’s upcoming earnings report date?
Royalty Pharma PLC’s upcoming earnings report date is Aug 12, 2026 which is in 41 days.
How were Royalty Pharma PLC’s earnings last quarter?
Royalty Pharma PLC released its earnings results on May 06, 2026. The company reported $1.296 earnings per share for the quarter, beating the consensus estimate of $1.214 by $0.082.
Is Royalty Pharma PLC overvalued?
According to Wall Street analysts Royalty Pharma PLC’s price is currently Undervalued.
Does Royalty Pharma PLC pay dividends?
Royalty Pharma PLC pays a Quarterly dividend of $0.235 which represents an annual dividend yield of 2.23%. See more information on Royalty Pharma PLC dividends here
What is Royalty Pharma PLC’s EPS estimate?
Royalty Pharma PLC’s EPS estimate is 1.28.
How many shares outstanding does Royalty Pharma PLC have?
Royalty Pharma PLC has 443,274,100 shares outstanding.
What happened to Royalty Pharma PLC’s price movement after its last earnings report?
Royalty Pharma PLC reported an EPS of $1.296 in its last earnings report, beating expectations of $1.214. Following the earnings report the stock price went up 0.554%.
Which hedge fund is a major shareholder of Royalty Pharma PLC?
Currently, no hedge funds are holding shares in RPRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Royalty Pharma Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$59.43 (18.86% Upside)
$59.43 (18.86% Upside)
Blogger Sentiment
Bullish
RPRX Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 469.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 0.4%
Last 30 Days ▼ 0.2%
Last 30 Days ▼ 0.2%
Technicals
SMA
Positive
20 days / 200 days
Momentum
58.96%
12-Months-Change
Fundamentals
Return on Equity
12.67%
Trailing 12-Months
Asset Growth
12.53%
Trailing 12-Months
Company Description
Royalty Pharma PLC
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
RPRX Company Deck
RPRX Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call was strongly positive: Royalty Pharma reported double-digit recurring revenue growth, attractive returns (ROIC ~14.1%, ROIE ~19.7%), robust cash generation ($722M portfolio cash flow), active capital deployment (>$0.5B) and strategic deal flow including R&D co-funding momentum (J&J and Teva deals) and high-impact clinical/regulatory wins (daraxonrasib, Avlayah, Myqorzo). Key risks highlighted were a material decline in milestone receipts (~53% drop), elevated interest expense timing, some market/policy headwinds (Promacta LOE, biosimilar Tysabri, MFN uncertainty) and optionality/execution risk in future co-funding tranches. Overall, the positive operating and balance-sheet trends and raised guidance outweigh the limited but meaningful risks discussed.View all RPRX earnings summariesRPRX Revenue Breakdown
93.34% Income from financial royalty assets
6.62% Other royalty income
0.04% Revenue from intangible royalty assets
RPRX Stock 12 Month Forecast
Average Price Target
$59.43
▲(18.86% Upside)
Technical Analysis
Ownership Overview
1.53% Insiders
19.32% Mutual Funds
31.27% Other Institutional Investors
36.29% Public Companies and
Individual Investors